Sofosbuvir–velpatasvir treatment of HCV with decompensated cirrhosis works in real world
02 Feb 2021
byJairia Dela Cruz
The combination of sofosbuvir plus velpatasvir does as well in the real world as in a Japanese phase III trial in hepatitis C virus (HCV) patients with decompensated cirrhosis, although there have been incidences of treatment discontinuation and liver disease-related death, as reported by a team of researchers.
